The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19

5Citations
Citations of this article
82Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

On March 11th, the World Health Organization (WHO) announced the unprecedented outbreak of “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2) to be a pandemic. Thus far, COVID-19 has infected over 58,229,138 individuals and caused 1,382,106 deaths worldwide. This has led to the re-purposing of available drugs under “off-label” use—drugs such as hydroxychloroquine and chloroquine. Both drugs have since been evaluated for their ability to treat COVID-19. Here, we summarize recent evidence regarding the use of hydroxychloroquine and chloroquine in hospitalized patients with COVID-19. All data is current as of November 23, 2020.

Cite

CITATION STYLE

APA

Aljadeed, R. (2022, December 1). The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19. Journal of Pharmacy Practice. SAGE Publications Inc. https://doi.org/10.1177/0897190021997399

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free